Search research articles
Contact Us
Filters
Showing results (91-100 of 109) with videos related to
Page
of 11
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
March 17, 2022
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
Matthew J Roberts, Andrew Morton, Nathan Papa, et al.
British Journal of Cancer
|
November 20, 2025
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy
Yiyue Zhu, Elaheh Zarean, Danmeng L Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 25, 2026
Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy
Raghava Kashyap, James P Buteau, Nathan Papa, et al.
BJU International
|
August 21, 2023
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy
Matthew J Roberts, Ciara Conduit, Ian D Davis, et al.
Journal of the American Medical Informatics Association : JAMIA
|
January 20, 2022
Knowledge and insights from a maturing international clinical quality registry
Fanny Sampurno, Christoph Kowalski, Sarah E Connor, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 27, 2025
Diagnostic Potential of <sup>68</sup>Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease
Zahra Sabahi, Andrew Nguyen, Keith Wong, et al.
European Urology
|
March 28, 2026
Prospective Comparison of <sup>64</sup>Copper [<sup>64</sup>Cu]SAR-bisPSMA vs <sup>68</sup>Gallium[<sup>68</sup>Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial)
Sobia Khan, Nathan Papa, Andrew Kneebone, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
David C Chen, James P Buteau, Nathan Papa, et al.
The Lancet. Oncology
|
August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, et al.
Nature Cancer
|
April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
Louise Emmett, Mina Swiha, Nathan Papa, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 109) with videos related to
Sort By:
Page
of 11
European Journal of Nuclear Medicine and Molecular Imaging
|
March 17, 2022
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
Matthew J Roberts, Andrew Morton, Nathan Papa, et al.
British Journal of Cancer
|
November 20, 2025
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy
Yiyue Zhu, Elaheh Zarean, Danmeng L Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 25, 2026
Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy
Raghava Kashyap, James P Buteau, Nathan Papa, et al.
BJU International
|
August 21, 2023
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy
Matthew J Roberts, Ciara Conduit, Ian D Davis, et al.
Journal of the American Medical Informatics Association : JAMIA
|
January 20, 2022
Knowledge and insights from a maturing international clinical quality registry
Fanny Sampurno, Christoph Kowalski, Sarah E Connor, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 27, 2025
Diagnostic Potential of <sup>68</sup>Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease
Zahra Sabahi, Andrew Nguyen, Keith Wong, et al.
European Urology
|
March 28, 2026
Prospective Comparison of <sup>64</sup>Copper [<sup>64</sup>Cu]SAR-bisPSMA vs <sup>68</sup>Gallium[<sup>68</sup>Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial)
Sobia Khan, Nathan Papa, Andrew Kneebone, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
David C Chen, James P Buteau, Nathan Papa, et al.
The Lancet. Oncology
|
August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, et al.
Nature Cancer
|
April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
Louise Emmett, Mina Swiha, Nathan Papa, et al.
Page
of 11